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Omeprazole, lansoprazole and pantoprazole are metabolized by several human
cytochromes P450, most prominently by CYP2C19 and CYP3A4. Only panto-
prazole is also metabolized by a sulfotransferase. Differences in the quantitative
contribution of these enzymes and in the relative affinities of the substrates
explain someoftheobserved interactions with carbamazepin, diazepam, pheny-
toin and theophylline and ofthe impact of the CYP2C19 (mephenytoin) genet-
ic polymorphism. Of these drugs, pantoprazole has the lowest potential for
interactions, both in vitro and in human volunteer studies.
INTRODUCTION
The proton pump inhibitors (PPIs)b omeprazole, pantoprazole and lansoprazole are
substituted benzimidazole sulfoxides with similar dose-efficacy profiles. Elimination of
these drugs occurs almost entirely by rapid metabolism to inactive or less active metabo-
lites, so that virtually no unchanged drug is excreted in urine and feces. The clearances of
PPIs are between 0.1 and 0.5 1/h/kg-body-weight and the plasma half-lives range from 0.3
to 2.2 hr [1-4]. Drug metabolism is subject to genetic and environmental variation, which
is a frequent cause ofpatient-to-patient differences in drug effects. The differences in the
metabolism ofthesedrugs, therefore, may favorably orunfavorably affect the potential for
interactions, enzyme induction and genetically polymorphic metabolism. On the other
hand, it is well known that the inhibitory effect of these drugs on acid secretion persists
for a long time, in spite oftheir rapid elimination.
METABOLISM OF OMEPRAZOLE, LANSOPRAZOLE AND PANTOPRAZOLE
Omeprazole
Omeprazole remains the most extensively studied ofthe PPIs in regard to its metab-
olism (Figure 1) [5, 6]. Omeprazole is primarily metabolized by aliphatic hydroxylation
of the pyridinyl methyl group to hydroxy-omeprazole and by oxidation of the sulfoxide
group to form omeprazole sulfone. Both metabolites are further metabolized to the
hydroxysulfone. In vitro studies in human livermircrosomes have also revealed some par-
ticipation of CYP2C19, CYP3A and CYP2D6 in the formation of secondary and minor
metabolites [6]. Two well-known cytochromes P450, CYP2C19 (S-mephenytoin hydrox-
ylase) and CYP3A4 (nifedipine oxidase), catalyze these reactions. CYP2C19 exhibits a
significant genetic polymorphism, and poor metabolizers ofS-mephenytoin are also poor
metabolizers ofomeprazole [7-10] (see below).
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Figure 1. Major metabolic pathways ofomeprazole and the enzymes involved. The size ofthe
arrows approximates the overall importance of the pathway for elimination.
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Figure 2. Major metabolic pathways oflansoprazole.
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Figure 3. Major metabolic pathways ofpantoprazole. Ml, M2 and M3 are the major metabolites
detected in serum.
Lansoprazole
The major metabolic pathway oflansoprazole involves the formation oflansoprazole
sulfone from the sulfoxide group (Figure 2). Lansoprazole sulfone is also the main
metabolite present in serum. Hydroxylansoprazole is also formed, but the hydroxylation
occurs at a different position (carbon 5 of the benzimidazole moiety) than for omeprazol
(5-methyl carbon of the pyridinyl group). Studies with human liver microsomes and
human hepatocytes in culture [1] indicate that, as with omeprazole, CYP3A4 is the major
enzyme involved in the sulfone formation. However, the enzymes catalyzing the hydrox-
ylation are less clearly identified and contributions of the cytochromes CYP3A4,
CYP2C18, CYP2C19 and others are suspected [ 1].
Pantoprazole
Pantoprazole (Figure 3) is also completely metabolized in the liver. It undergoes 0-
demethylation by CYP2C19, which is followed by sulfate conjugation and some sulfone
or sulfide formation, eitherby oxidation orreduction ofthe sulfoxide group [3, 4]. Recent
in vivo and in vitro studies in human liver microsomes suggest that in addition to a cytoso-
lic sulfotransferase, CYP2C19 and CYP3A4 affect the clearance of pantoprazole, i.e.,
poor metabolizers ofpantoprazole were also poor metabolizers ofmephenytoin (Table 1,
W.A. Simon, unpublished data). The same studies suggest that additional enzymes such
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as CYP2C9 and CYP2D6 may contribute in aminorway to some ofthe reactions involved
in the metabolism ofpantoprazole.
In summary, CYP2C19 and CYP3A4 (and in the case of pantoprazole a sulfotrans-
ferase) are sequentially and alternatively involved in the metabolism of these drugs.
However, the affinities of these enzymes for the different substrates and metabolites
apparently vary remarkably. CYP2C19 and CYP3A4 are well-studied human drug-metab-
olizing enzymes and their substrates, inhibitors and inducers have been extensively
reviewed [12, 131.
ROLE OF THE CYP2C19 POLYMORPHISM FOR THE KINETICS OF PPI'S
CYP2C19 or S-mephenytoin 4'-hydroxylase manifests a common genetic polymor-
phism [14]. Two mutations, ml and m2, ofthe CYP2C19 gene have recently been demon-
strated to cause loss of function alleles of this enzyme [15, 16]. Homozygous carriers of
the mutation, thus, completely lack CYP2C19 enzyme and are so-called poor metaboliz-
ers (PMs) ofmephenytoin. These PMs have an up to 10-foldhighervalue ofthe areaunder
the plasma concentration-time curve ofomeprazole [7, 8, 17-19] as compared to extensive
metabolizers. 2.5 to 6 percent ofCaucasians and up to 30 percent of Oriental individuals
are PMs [20]. During treatment with 40 mg/d omeprazole, approximately 80 percent of
omeprazole clearance can be attributed to CYP2C19. When the dose is increased,
CYP2C19 becomes limiting, and non-linear saturation kinetics may occur. Thus, at high
doses, the kinetic parameter in EMs is shifted toward values observed in PMs who do not
have a CYP2C19 enzyme. For omeprazole, at least, CYP3A4 appears to function as a
high-capacity enzyme and prevents accumulation ofvery high omeprazole concentrations.
Under these condition, CYP3A4 may become the major target ofdrug interaction. Similar
studies have not been done for lansoprazole and pantoprazole, but as already discussed,
CYP2C19 also plays a role in the metabolism of these drugs. PMs ofmephenytoin were
also PMs ofpantoprazole (Table 1), and lansoprazole was shown in in vitro studies to be
in part metabolized by CYP2C19.
The relevance ofthe polymorphism for the efficacy and safety ofacid inhibitory ther-
apy by PPI's has not been evaluated. Chang et al. [18] reported higher gastrin levels in
PMs after eight daily doses (20 mg) of omeprazole in PMs as compared to EMs, but no
studies on acid secretion are yet available. This would be ofparticular importance in pop-
ulations with a high percentage of PMs of mephenytoin. Moreover, gastrin levels were
also higher in heterozygous carriers of a mutant alleles of CYP2C19. This finding sug-
gests that approximately 60 percent of Orientals (including the homozygous and het-
erozygous carriers of CYP2C19 mutant alleles) may have a slower metabolism of
CYP2C19 substrates than the majority ofCaucasians.
INDUCTION OF DRUG-METABOLISM BY PPI'S
Omeprazole and lansoprazole induce the synthesis of CYPlAl and CYP1A2 [21].
For omeprazole, induction of CYPlA enzymes has been demonstrated in biopsies of
Table 1. Plasma half lives (h + S.D.) of omeprazole and pantoprazole in extensive
metabolizers and poor metabolizers of mephenytoin. The phenotype for S-mepheny-
toin hydroxylation was determined by the urinary S/R enantiomeric ratio.
Omeprazole* Pantoprazole**
Extensive metabolizers 0.69 + 0.41 (6)t 1.3 + 0.9 (11)
Poor metabolizers 2.30 + 0.44 (6) 7.6 + 1.1 (4) (range 6.2-9)
*Data from [8]. **Data from Byk Gulden, Konstanz, Germany. tNumber of volunteers.
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human liver [21] and gut [22]. This effect has also been demonstrated in vivo in human
volunteers by increased N3-demethylation of caffeine after omeprazole administration
[24, 25] or increased clearance of theophylline after lansoprazole treatment [26]. In
human hepatocyte cultures [27], CYP3A4 also was induced by omeprazole and its sul-
fone, and by lansoprazole. The induction effect is concentration-dependent and, thus,
occurs at lower doses in poor metabolizers ofmephenytoin. The molecular mechanism of
the induction of CYPIA1/2 and CYP3A4 by these drugs is not exactly known [28, 29].
These observations have generated a debate on the risk of induced P450s for carcinogen-
esis, since both CYPlAl and CYP3A4 can activate or inactivate procarcinogens. For
some procarcinogens, induction can be an advantage, for others a disadvantage. Lack of
induction ofantipyrine, caffeine and theophylline clearance by pantoprazole suggests that
this drug has little or no potential for induction [30, 31].
DRUG INTERACTIONS
PPIs interact with cytochromes P450 not only as substrates, but also as competitive
inhibitors and inducers. Omeprazole inhibits the clearance of diazepam by 26 to 54 per-
cent [32, 33], and this inhibition is more apparent in individuals ofthe mephenytoin exten-
sive metabolizer phenotype (EMs), indicating that at therapeutic concentrations omepra-
zole and diazepam compete for the same site on CYP2C19. Neither lansoprazole [34] nor
pantoprazole [35] seem to affect diazepam kinetics. A decrease in the clearance ofpheny-
toin [36] and carbamazepin [37] points to interaction of omeprazole with other
cytochromes P450, presumably ofthe CYP2C9 subfamily. Lansoprazole and pantoprazole
Table 2. Interactions ofPPIs with other drugs.
Drug tested Major P450 Omeprazole Lansoperazole Pantoprazole
Theophylline CYP1A2 No IA (TCI) No IA
Caffeine CYPlA2 IM NT No IA
Phenytoin CYP2C9 JkCI No IA No IA
Warfarin CYP2C9 (4ICl) No IA No IA
Carbamazepin CYP2C8 ICI DC NT No IA
Diclofenac CYP2C9 NT NT No IA
Phenprocoumon ? NT NT No IA
Mephenytoin CYP2C19 JtM NT No IA
Diazepam CYP2Cl9 JICI No IA No IA
Debrisoquine CYP2D6 No IA NT No IA
Propanalol CYP2D6 + others No IA No IA NT
Metoprolol CYP2D6 No IA NT NT
Nifedipin CYP3A4 (JkCl?) NT No IA
Cyclosporine CYP3A4 No IA NT NT
Lidocaine CYP3A4 No IA NT NT
Quinidine CYP3A4 No IA NT NT
Contraceptives CYP3A4 NT Eff. on ovul.? No IA
Alcohol CYP2E1 NT NT No IA
Antipyrine CYP3A/2C/1A2 (1Cl) (TCl) No IA
Methotrexate renal excr. NT NT
Digoxin Absorption (I absorption) NT No IA
Bismuth Absorption I absorption NT NT
IA = interaction; Cl = clearance; M = metabolism; NT = not tested; (= ofquestionable signifi-
cance.
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apparently do not interact with CYP2C19 and other CYP2C substrates. The induction of
CYP1A2 by omeprazole and lansoprazole is reflected by the increased clearance of caf-
feine [24, 25] and theophylline [26], respectively. No clinically relevant interactions ofthe
three drugs with most CYP3A4 substrates have been observed. Extensive studies withpan-
toprazole showed this drug to have the lowest potential of these three drugs for metabolic
interactions in vitro and in vivo. The present data-base on interactions is summarized in
Table 2 and References 1-4, 30, and 38.
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